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Background: Child diarrhea persists as a leading public health problem in India despite evidence supporting zinc
and low osmolarity oral rehydration salts as effective treatments. Across 2 years in 2010–2013, the Diarrhea Alleviation
using Zinc and Oral Rehydration Salts Therapy (DAZT) program was implemented to operationalize delivery of these
interventions at scale through private and public sector providers in rural Gujarat and Uttar Pradesh, India.
Methods/Design: This study evaluates the cost-effectiveness of DAZT program activities relative to status quo conditions
existing before the study, comparing a Monte Carlo simulation method with net-benefit regression, discussing
the strengths and weaknesses of each approach. A control group was not included in the ‘before and after’ study
design as zinc has proven effectiveness for diarrhea treatment. Costs will be calculated using a societal perspective
including program implementation and household out-of-pocket payments for care seeking, as well as estimates of
wages lost. Outcomes will be measured in terms of episodes averted in net-benefit regression and in terms of the years
of life lost component of disability-adjusted life years in the method based on Monte Carlo simulation. The Lives
Saved Tool will be used to model anticipated changes in mortality over time and deaths averted based on
incremental changes in coverage of oral rehydration salts and zinc. Data will derive from cross-sectional surveys
at the start, midpoint, and endpoint of the program. In addition, Lives Saved Tool (LiST) projections will be used
to define the reference case value for the ceiling ratio in terms of natural units.
Discussion: This study will be useful both in its application to an economic evaluation of a public health program in
its implementation phase but also in its comparison of two methodological approaches to cost-effectiveness analysis.
Both policy recommendations and methodological lessons learned will be discussed, recognizing the limitations in
drawing strong policy conclusions due to the uncontrolled study design. It is expected that this protocol will be useful
to researchers planning what method to use for the evaluation of similar before and after studies.
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Worldwide, diarrhea is the fourth leading cause of mortality
among children under 5, accounting for 9% of total deaths
[1]. In 2011, over 700,000 children died due to diarrhea [2],
with eighty percent of cases occurring in East Asia and the
Pacific, South Asia, and Africa, and 33% in South Asia
alone [3]. However, diarrhea mortality is a solvable health
problem, with this number of deaths having fallen from 4.6
million in 1980 [4]. India is a priority area for addressing
the remaining burden, recognized as one of 15 countries
that account for 53% of total episodes worldwide, with
312.22 million episodes and 205,600 deaths each year
nationwide [2].
Since becoming widely used for diarrhea treatment in
the 1980s [5], oral rehydration salts (ORS) have been
instrumental in contributing to declines in prevalence.
ORS prevents mortality by reducing the loss of fluids and
electrolytes and death due to dehydration [6]. However,
coverage of ORS in India remains low at less than 30%,
and one out of ten children nationwide continues to
experience diarrhea in any 2-week period [7].
The 2004 United Nations Children’s Fund (UNICEF)/
World Health Organization (WHO) Joint Statement for the
Clinical Management of Acute Diarrhea revised the global
standards for acute diarrhea management to include ‘20 mg
per day of zinc supplementation for 10–14 days (10 mg per
day for infants under 6 months old)’ [8]. The therapeutic
effect of zinc is to strengthen the immune system, improve
absorption of water and electrolytes in the intestines,
enhance the regeneration of the gut epithelium, increase
levels of enzymes in the epithelium, and help the body clear
pathogens from the intestines [9]. As a complement to
ORS, zinc has been shown to reduce incidence [8], preva-
lence [10], and duration of diarrhea episodes [8,9,11-13].
Evidence on whether zinc reduces all-cause mortality is
scarce, with one trial using non-injury mortality as a proxy
for diarrhea deaths [9], not testing mortality as an outcome
[11], or not having sufficient power to detect a significant
difference in mortality [13]. Baqui et al. (2002) showed a
non-significant difference in non-injury deaths, controlling
for other factors, and authors concluded that the effect on
mortality was due to zinc [9]. Applying the Child Health
Epidemiology Reference Group (CHERG) Rules for
Evidence Review indicates that mortality reduction could be
as much as 23%, and ideal data, from randomized controlled
trials (RCTs), is unlikely to emerge as the strength of
evidence in support of zinc makes these trials unethical [14].
In India, evidence on the effectiveness of zinc for the
management of acute diarrhea is mixed between studies
showing an effect [10,15,16], and those with no or marginal
effects [17-19]. Of these, one was conducted in a rural
community setting [10]. This randomized controlled trial
was carried out in six primary health care (approximately
30,000 population each centers) in Haryana [10], whichprovided an intervention that included training and supply
of zinc and ORS to Anganwadi Workers and primary
health center staff. This intervention nearly doubled the
proportion of patients that received treatment between 3
and 6 months. In addition, the intervention led to signifi-
cant reductions in diarrhea prevalence and the rate of
hospitalizations due to diarrhea.
Building upon the success of effectiveness trial activities in
Haryana, programmatic efforts to introduce zinc and ORS
have been initiated throughout the last decade in India.
Between 2005–10, the Point-of-Use Water Disinfection
and Zinc Treatment (POUZN) project was implemented
and found to be effective in improving both supply and
demand for zinc. This program worked with pharmaceut-
ical companies, channeled zinc through both the public
and private sectors, collaborated with non-governmental
organizations (NGOs), recruited support from key opinion
leaders, provided training to detailers, stimulated prescrib-
ing practices among rural medical providers (RMPs), and
promoted products with social marketing.
In 2010, the Diarrhea Alleviation using Zinc and ORS
Therapy (DAZT) program expanded upon POUZN
activities in scale and scope to make zinc and ORS available
for the management of diarrhea through private and public
sector providers in 6 districts of Gujarat and 12 districts of
Uttar Pradesh (UP) states of northern India. DAZT is
similar to POUZN in the characteristics mentioned above,
but differed in that DAZT did not provide point-of-use
water interventions, monitored zinc purchase and sales
with short messaging service (SMS) in the private sector,
and promoted zinc through informational booths in private
clinics and hospitals. A full description of DAZT program
activities is presented in Table 1.
The objective of this study is to evaluate the cost-
effectiveness of the DAZT program under real-world
conditions compared to the status quo existing before the
intervention was introduced in the study area. Two
analytical approaches will be used to meet this objective:
calculation of cost-effectiveness using a Monte Carlo
Simulation method with patient level data [20], and
calculation of cost-effectiveness using a net-benefit regression
approach to control for covariates [21].
Both community-based [Lefevre et al. forthcoming,
Bishai et al. forthcoming] and model-based evidence
[4,22] suggest that zinc supplementation to treat diarrhea
is cost-effective in low- and middle-income countries
(LMICs), although hospital-based studies do not find a
significant difference in cost [23], effect [19], or both [24]
between children receiving zinc and those that do not.
These studies were conducted across a wide range of
settings; however, none of them can be classified as
implementation research. This study will evaluate the
cost-effectiveness of the DAZT program and further
discourse on approaches to economic evaluation of health
Table 1 Diarrhea Alleviation through Zinc and Oral Rehydration Therapy (DAZT) Program Summary
Sectors Program activities
Public sector Micronutrient Initiative (MI)
State-level policy changes • Permission to implement DAZT was formalized through Memorandums of Cooperation between MI and the state
government, and MI and the Department of Health and Family Welfare of Gujarat
• In Uttar Pradesh, less formal permission was obtained from the government
• Commitment from the Department of Women and Child Development in Gujarat
• Both states added zinc to their NRHM guidelines and essential drug lists
Programmatic planning National Rural Health Mission (NRHM) Program Implementation Plans (PIPs) were changed to include the procurement
of zinc and ORS
Training Three levels of training were conducted including (1) district level supervisors, (2) Block level supervisors and health
workers, and (3) ASHAs and AWWs. Trios, a Delhi-based agency, conducted training in Gujarat, and three NGOs
conducted the training in UP
Supply • Supply was provided by two pharmaceutical companies including Healthy Life Pharma and FDC limited assuming
that the public sector would treat 10% to 15% of diarrhea cases
• Kits contained two ORS sachets and 14 taste masked zinc tablets, a measuring cup, and an informational leaflet
for caregivers
Procurement • Healthy Life Pharma and FDC limited provided the first procurement of kits
• In Gujarat, in phase 1 (2011), MI provided ORS and zinc and in phase 2 (2012), MI limited its provision to zinc only
(government procured ORS)
• In 2013, the state governments disbursed funds to all districts to purchase zinc
• ANMs may have used supply procured from sources other than MI
Incentives Incentives were delivered to ASHAs, AWWs, and ANMs at monthly meetings to increase attendance rates
Distribution • Supplies were distributed from Healthy Life Pharma to district medical stores, to district hospitals or block offices/
CHC/PHC, to HSC-ANMs and CDPOs, to ASHAs and AWWs
• ANMs informed PHC block level supervisors about needs; supplies were redistributed from areas of surplus to areas
of shortage
Monitoring and supervision • Supportive supervisors and MI divisional coordinators provided supportive supervision at the district, block,
sub-center, and village levels in the form of data validation and capacity building
• These mechanisms complemented existing monitoring mechanisms of the public health system
• Supervisors attended monthly meetings of ASHAs, AWWs, ANMs, spent at least 18 days monitoring field staff visits,
provided staff with hands on training when necessary, analyzed service provider knowledge and skills, stock
status, and caregiver compliance with treatment
Private sector Family Health International-360 (FHI-360)
Policy changes • Memorandums of understanding were signed with prominent professional medical organizations (IAP, IMA, and
other local medical associations)
• Partnered with NGOs, pharmaceutical companies, and homeopathic and alternative medicine associations
Programmatic planning An implementation plan was developed which involved a push and pull strategy—push: changed prescription
among key opinion leaders in the medical community and created IEC materials with medical experts about
diarrhea management and marketed ORS and zinc to RMPs and drug sellers; pull: natural demand creation for ORS
and zinc within this group
Training • NGO and pharmaceutical staff trained for three days in diarrhea epidemiology, importance of zinc and ORS, correct
dosage and regulatory guidelines, and promotional strategies for effective product placement
• Professional organization were provided with continuing medical education
• DAZT corner staff were trained on selected topics from the three day training schedule
• In UP, ten RMPs from the Sehat Mitra project were trained with an adapted version of the three day training session
Supply Local manufacturers were linked with informal providers in designated areas
Procurement Utopia Pharmaceuticals and Prayas manufactured and distributed zinc in UP, and RMPs procured zinc from West Coast
Pharmaceuticals and generic brands from NGOs in Gujarat, with procurement plans accounting for different levels of
demand according to season
Incentives Pharma companies provided field representatives with commissions of 2 Rupees for each sale above 200
Distribution Generic distributors supplied District Coordinator offices, which distributed to the Tehsil Coordinator based on demand
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Table 1 Diarrhea Alleviation through Zinc and Oral Rehydration Therapy (DAZT) Program Summary (Continued)
DAZT corners Staffed informational booths in private clinics and hospitals to create awareness among caregivers and remind providers to
prescribe zinc
Sehat Mitra project In Faizabad Uttar Pradesh, a pilot project to provide ORS and zinc in patient’s homes by RMPs traveling on bicycles
Monitoring and supervision • Monthly NGO and pharma staff meetings, validation of data and reports, SMS messaging from the field
• FHI staff attended monthly meetings, district coordinators spent a lot of time in the field working with new staff
Accredited Social Health Activists (ASHAs); Anganwadi Workers (AWWs); Auxiliary nurse midwives (ANM); Child development project officer (CDPO); Community
health centers (CHC); Diarrhea Alleviation and Zinc Therapy (DAZT); FDC Limited pharmaceutical company (FDC); Health subcenter (HSC); Indian Academy of
Pediatrics (IAP); Indian Medical Association (IMA); Information, education, communication (IEC); Micronutrient Initiative (MI); Non-governmental organizations
(NGO); National Rural Health Mission (NRHM); Oral rehydration salts (ORS); Primary health centers (PHC); Program Implementation Plans (PIP); Rural medical
providers (RMP); Short messaging service (SMS); Uttar Pradesh (UP).
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logically, examples of cost-effectiveness analyses evaluat-
ing ‘before and after’ studies designs are emerging (for
example [25,26]); however, these types of studies are not
well established in the literature. Thought is needed to
identify special considerations that may be relevant to
before and after study evaluations. The International
Society for Pharmacoeconomics and Outcomes Research
(ISPOR) has developed guidelines for using ‘real-world data’
[27], but guidelines for conducting cost-effectiveness ana-
lysis (CEA) alongside ‘before and after’ studies do not exist.
Alternative methods for conducting CEA are sometimes
used to evaluate a single dataset to make methodological
points, assess validity, and test robustness of results accord-
ing to structural uncertainty [21,28,29]. Two of several
analytical approaches available for CEA include Monte
Carlo Simulation methods with patient level data [20] and
net-benefit regression [21]. The latter framework combines
established methodologies from economic evaluation and
econometrics and has the advantage of being able to adjust
for imbalances in confounding variables. Net-benefit regres-
sion methodology can be used for randomized [21,30] and
non-randomized studies [31,32], although the case can be
made that it is even more appropriate for non-randomized
study designs as covariates are more likely to be unevenly
distributed across study arms [33]. Bootstrapping confi-
dence intervals presents the problem of ambiguity in incre-
mental cost-effectiveness ratios (ICERs), although this
problem can be circumvented in both methods using the
net-benefit statistic, and both net-benefit regression and
bootstrapping can be used to generate cost-effectiveness
acceptability curves (CEACs). The bootstrap approach
offers one advantage in that uncertainty around program
costs can be simulated by resampling from parametric
distributions fit to the data, while program costs are divided
evenly across patients within each arm in the net-benefit
regression approach [21] or are assumed to cancel out
across study arms or phases [31]. Deterministic calculations
and net-benefit regression are commonly evaluated in
tandem in the literature [21,31,32], but scope exists to add
thought on comparisons between bootstrapping and net-
benefit regression. It is anticipated that documentingthought behind choosing between these analytic frame-
works will be useful to researchers facing similar questions
about evaluation of programs with similar study designs.
Policy recommendations from the completed research
will add to the growing literature evaluating the cost-
effectiveness of zinc for diarrhea treatment in low- and
middle-income countries. Findings will be timely as India is
developing a Health Technology Assessment (HTA)
program in collaboration with the UK National Institute of
Health and Care Excellence [34], in which the importance
of CEA in policy making can be expected to increase. In
addition, local capacity to produce zinc is rapidly expanding
including Bharat Immunologicals and Biologicals Corpor-
ation Limited (BIBCOL), which is a government-owned
corporation with the capacity to produce 240 million of
20 mg scored tablets of zinc sulfate per year [35]. Currently,
about 40 private companies are producing zinc for local
and international markets.
This article presents the DAZT program in India. Analytic
methods for evaluating cost-effectiveness are described and
compared, in addition to methods for assessing wealth
quintile using principal components analysis. Strengths and
limitations of the study are discussed, followed by argu-
ments against targeting zinc according to subgroup, and
considerations necessary for drawing conclusions about
generalizability.
Methods
Setting and study design
Gujarat and Uttar Pradesh are states in northwest and
north India, respectively, which, along with Madhya
Pradesh, contribute to half of the diarrhea burden in India.
The majority of these states are rural, access to basic
sanitation is limited, and most adults have only primary
education or less; although signs exist that these states are
progressing through the ‘demographic transition’ [36,37].
In 2010, the DAZT program was introduced through both
the public and private sectors in 6 districts of Gujarat and
12 districts of Uttar Pradesh. Care seeking for diarrhea
was mostly from private doctors, and shifts in use of the
health system were seen from private hospitals to community
health workers. Data were collected on the last episode
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Given that the intervention is implemented on a system-
wide level, and the effectiveness of zinc has been
established for diarrhea treatment [14], a ‘before and after’
study design was chosen [38]. This evaluation compares
the costs and health outcomes associated with the DAZT
intervention after 2 years of implementation (Table 1)
with those that preceded the intervention. This time frame
was considered appropriate as it represented conditions
after which the program was fully implemented. Outcome
indicators include caregiver knowledge, incidence of
diarrhea, treatment seeking, source of care, use of zinc,
cost of treatment, and cost-effectiveness.
Sample size and power calculation
The sample size for the main effects study was calculated
according to standard methods for rates calculated
through cluster randomized designs. Calculations used
ORS coverage rates in the initial survey since very few
children received zinc before the start of the program, and
delivery of ORS and zinc were assumed to be linked. Ac-
tual sample sizes achieved for each survey are presented
in Table 2. Using sample sizes from the main study, power
to detect meaningful differences will be calculated for our
cost-effectiveness estimate. Two formulas from Glick et al.
[39] will be merged to determine power for cost-
effectiveness using a novel approach to calculating the
reference case ceiling ratio from an estimate based on per
capita gross national income (GNI) and Lives Saved Tool
(LiST) outputs of deaths averted/episodes averted.
Sampling and data collection
Data were collected through closed-ended survey question-
naires administered to a sample of caregivers of children
2–59 months old. In each survey, information was elicited
on caregiver’s knowledge of diarrhea management, illnesses
in the past 2 weeks, care seeking, treatment received,
wealth quintile, and demographic characteristics of the
household. Data on economic costs will be collected
prospectively throughout implementation to capture pro-
gram and incremental users' costs.
Program costs will be based on the financial records of
the international NGOs working with public and private
sector partners. To enhance generalizability, capital costs ofTable 2 Sample sizes for each survey
Survey Number of participants Dates
Gujarat Uttar Pradesh
Starting point 4,200 3,889 March 22–Ma
Monsoon season June through
Midpoint 1,072 1,790 September 1
Endpoint 5,080 1,001 September 2
aAlthough peak diarrhea season lasts until November.furniture and equipment will be based on the original price
paid inflated to 2014 and annualized using the full lifespan
of the item and a 3% discount rate [20]. Donated labor,
equipment, and facilities will be valued according to market
prices; transfer payments such as taxes and subsidies will
be removed; and rent costs will be used to represent build-
ing costs [40]. Since results will be presented in US$, it will
not be necessary to adjust non-traded items to correct for
price distortions [41]. Users' cost will be derived from
reported out-of-pocket payments for care seeking and
wages lost.
Conceptual framework
A conceptual framework has been developed to identify
important model variables based on categories from
Andersen and Newman [42]. This framework consists of
three main categories of interacting factors that are associ-
ated with treatment seeking including predisposing, enab-
ling, and need factors; as indicated in Figure 1. The model
was limited to only children that sought care for diarrhea,
although other symptoms associated with diarrhea were
assessed in caregiver surveys. If treatment was sought and
given, economic costs could result, which are an import-
ant component of cost-effectiveness. In our framework,
knowledge differs from the concept described in Andersen
and Newman [43] in that our data describes awareness of
the treatments, where they consider values and beliefs
about treatment. All of these variables were justified by
literature, and will be included regardless of whether their
coefficients in our models are significant to ensure that
variances are correctly estimated.
Descriptive statistics
Descriptive statistics of the parameters (Table 3) will be
calculated according to their means, confidence intervals,
and p-values reflecting the extent of difference between
arms. Comparisons will be made at the start and endpoint
of the program. Stata svy commands will be used to
account for clustering with F-tests used to evaluate the
significance of differences between groups. As costs are
not normally distributed, significance of differences
between components listed in Table 4 at the start and end
of the program will be calculated using confidence intervals
with bootstrapped standard errors.y 10, 2011 Gujarat; April 1–June 21, 2011 Uttar Pradesh
beginning of Septembera
–October 8, 2012 Gujarat; May 24-October 4 2012 Uttar Pradesh
8–November 18, 2013 Gujarat; August 25–October 12, 2014 Uttar Pradesh
Figure 1 Conceptual framework based on Andersen and
Newman [42].
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The cost of the DAZT program from 2011 to 2013 (Gujarat)
and 2014 (Uttar Pradesh) will be calculated from the
societal perspective according to Saving Newborn Lives
guidelines and standard textbooks [20,40,43]. The societal
perspective reflects the incremental costs incurred by imple-
menting agencies, government providers, and households.
Program costs will be divided into capital costs and recur-
rent costs, with data derived from program records, primary
sources, and interviews with individuals responsible for
implementation. Capital costs will be annualized and dis-
counted according to a rate of 3% according to the standard
rate for economic evaluation in International Health [44].
Consumer price indices from the International Monetary
Fund (IMF) will be used to inflate costs to 2014. Costs will
be converted to US$ using exchange rates from OANDA.com. Incremental government provider costs will be derived
using reported estimates of time spent on the provision of
diarrhea treatment services by public sector providers.
Economic costs to caregivers for diarrhea treatment of the
episodes in the last 2 weeks will be evaluated according to
data collected through household questionnaire and consist
of direct medical costs of treatment, direct non-medical
costs (transportation), and indirect costs (wages lost by
caregivers) [45]. No adjustments will be made to collected
data to approximate opportunity costs.
Health outcomes
In the standard cost-effectiveness calculation, health out-
comes will be derived from incremental changes in cover-
age measured in cross-sectional household surveys and
inputted into LiST. LiST will estimate the incremental
number of lives saved from the study’s start to its comple-
tion. The years of life lost (YLL) component of disability-
adjusted life years (DALYs) will be calculated using the
standard formula from the Global Burden of Disease study
[46]. A life expectancy estimate will be taken from WHO
life tables representing the midpoint between 1–4 years
old. A discount rate of 3% will be used in reference case
calculations, and age weighting will not be used to be
consistent with the Disease Control Priorities Project
second edition (DCP2) [41]. Long-term sequelae such as
acute cognitive and psychomotor development effects in
young children, the effects of diarrhea on stunting [4], and
obesity and related conditions that can occur later in life
(cardiovascular disease and diabetes) [47] were not
measured and will not be considered. The net-benefit
regression approach will be limited to episodes averted as
it is impossible to know the specific long-term health
outcomes for individual patients. Limitations of drawing
data from a single uncontrolled study are recognized [48],
although cost-effectiveness analysis is often conducted on
data from a single effectiveness study, and conditions in
the study sites are not atypical of other relevant settings in
low- and middle-income countries.
Cost-effectiveness analysis
Cost-effectiveness will be calculated using two different
approaches including 1) Monte Carlo Simulation with
patient level data [20] and 2) a net-benefit regression-based
approach [21].
Monte Carlo Simulation with patient level data approach
to cost-effectiveness analysis
Initial cost-effectiveness calculations will be generated
through Monte Carlo simulation to evaluate uncertainty in
economic costs to caregivers and health outcomes, using
an additional simulation technique to account for the
uncertainty in program costs. Samples of economic costs to
caregivers and health outcomes will be drawn from the data




Demographic characteristics Household size Continuous variable (min = 2 people, max = 23 people in Gujarat
and 32 in Uttar Pradesh)
Child sex Male =0, female =1
Child age Continuous variable (min =2 months, max =59 months)
Characteristics of the social
structure
Mother’s education No or primary education =0, primary education or above =1,
secondary education or above =2, tertiary education or above =3
Father’s education No or primary education =0, primary education or above =1,
secondary education or above =2, tertiary education or above =3
Scheduled caste Not a scheduled caste =0, scheduled caste =1
Scheduled tribe Not a scheduled tribe =0, scheduled tribe =1
Other backwards caste Not another backwards caste =0, other backwards caste =1
Caregiver knowledge Knowledge about ORS No knowledge =0, knowledge =1
Knowledge about zinc No knowledge =0, knowledge =1
Enabling factors DAZT program Initial survey, final survey
Below poverty line card No BPL card =0, BPL card =1
Very poor Any other wealth quintile =0, second wealth quintile =1
Poor Any other wealth quintile =0, third wealth quintile =1
Less poor Any other wealth quintile =0, fourth wealth quintile =1
Least poor Any other wealth quintile =0, fifth wealth quintile =1
Need factors Duration of diarrhea Continuous variable (min = 0 days, max = 15 days in
Gujarat and 32 in Uttar Pradesh)
Blood in the stool No blood in the stool =0, Blood in the stool =1
Treatment seeking Seek treatment outside of the home No treatment sought outside of the home =0, treatment sought =1
Treatment given Given ORS No ORS =0, given ORS =1
Given zinc No zinc =0, given zinc =1
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ment. Uncertainty around program costs will be simulated
by drawing data from gamma distributions derived from
most likely, low and high estimates for each component.
This process will be repeated 10,000 times to ensure that
tails of standard error distributions are filled and increase
stability in results since available computing power is
sufficient. ICERs will be calculated, and uncertainty will be
quantified using a bootstrap approach, choosing the values
representing the upper and lower 2.5% of data. To
disambiguate negative ICERs and show the probability of
cost-effectiveness according to different values of the
ceiling ratio, CEACs will be calculated, using per capita
GNI as the reference case threshold [49] (US$1,740 in
Gujarat, $571 in Uttar Pradesh). Calculations will be
performed using Microsoft Excel with the Palisade at-risk
add-in.
Net-benefit regression-based approach to cost-effectiveness
analysis
A second approach to calculating cost-effectiveness will
be taken according to net-benefit regression methods tocontrol for imbalances in covariates arising from the non-
randomized study design [21,31,32]. This method uses
patient-level data of economic costs to caregivers and
health outcomes, distributing program costs from the last
year of the program evenly across children in the endpoint
survey. A modification of the net-benefit statistic will
serve as the dependent variable, given that outcomes are
measured in terms of a health gap measure instead of
health expectancy measure [50]. This formulation adds
costs to outcomes expressed in monetary terms instead of
taking the difference as is done in standard net-benefit
calculations. The coefficient on a treatment variable that
distinguishes between the starting point and endpoint of
the program will be used to represent incremental net
benefit. One sided p-values from the treatment variable will
be used to construct CEACs, using results from a series of
regressions that use different values for the ceiling ratio.
Due to the non-normality in the distribution of residual
values, a generalized linear model using a gamma distribu-
tion will be used. Huber-White robust standard errors will
be used to address heteroskedasticity, and clustering will
be accounted for consistent with study design. Data will be
Table 4 Descriptive statistics about costs
Costs according to source of care and components according
to outpatient, inpatient, and home care
Costs according to source of care
Public source—facility care PHC, government hospital, government dispensary
Auxiliary nurse midwife, sub-center
Public source—community care Anganwadi worker/center
ASHA





Charitable hospital, NGO, trust
Cost components according to outpatient, inpatient, and home care
Direct medical Consultation
Dispensing
Purchase of zinc (tablets or syrup)
Purchase of ORS (packets)




Direct nonmedical Transportation (round trip)
Indirect costs Wages lost
ASHA: Accredited Social Health Activist; NGO: Non-governmental organization; ORS: Oral rehydration salts; PHC: Primary health center.
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spline term improves model fit. The importance of influen-
tial data points will be checked using DFBETAs, excluding
caregivers with the top ten DFBETA scores in sensitivity
analysis. Calculations will be performed in Stata 13, using
standards for good practice for using statistical regression
models in economic evaluations [51].
Principal components analysis
Principal components analysis will be used to categorize
caregivers according to wealth quintile using established
methods [52,53]. While no established rules exist for select-
ing variables, broad categories of assets will include durable
asset ownership, housing characteristics, and access to basic
services based on precedent [52]. To avoid illogical rank-
ings [54], only those variables with a prevalence between
5%–95% will be retained. While these thresholds are
arbitrary, they are consistent with rules of general inference
to define a value with low probability. Eigenvalues will be
generated in Stata, which represent linear combinations of
variables that capture the maximum amount of remaining
uncertainty in the data for each component. The compo-
nent with the greatest eigenvalue will be selected forcreating a wealth index, as higher order components have
been shown not to be important in a previous study and
convention has become to create wealth indices on only
one component [52]. Factor loadings will be assessed to
determine what variables align the most closely with the
principal component and evaluate whether its representa-
tion of wealth has face validity. Caregivers will be divided
into quintiles, and variables for regression analyses will be
based on these quintiles. The scale will be validated accord-
ing to a Cronbach’s alpha greater than 0.6.
Ethical approval and study status
For the main study, ethical approval was obtained from SAS
and the Johns Hopkins Bloomberg School of Public Health
(JHSPH) Institutional Review Board (IRB). DAZT project
activities commenced in late 2010 and will span through
2014.
Discussion
Economic evaluation provides insights into the appropri-
ate allocation of resources, and yet the number of cost-
effectiveness and cost-utility analyses alongside programs
at scale - where large amounts of resources are invested -
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in methods adopted have implications on the validity of
findings and on their generalizability. Economic evaluation
has traditionally focused on the cost of an intervention to
produce a desired health outcome in studies based on
modeled evidence or data collected alongside randomized
controlled trials. As the number of interventions with
known impact on health increases, there is an increased
need for evidence on ways of operationalizing delivery of
these health services to ensure high coverage, quality, and
cost-effectiveness.
The aims of the DAZT intervention are to improve the
supply, demand, and prescribing practices for treatment of
diarrhea in children with zinc and ORS. These objectives
are consistent with goals of The Indian Academy of
Pediatrics [55], WHO [56], and UNICEF [3] who have all
endorsed zinc supplementation to ORS for the treatment of
diarrhea in children. In addition, the Government of India
has established the Oral Rehydration Therapy Program to
increase awareness about causes of diarrhea and its
treatment among mothers and communities [7], and results
of this study may be used to support this program.
This study will provide an evaluation of a zinc delivery
strategy in a resource-constrained setting, in addition to a
comparison of methods for cost-effectiveness analysis. The
calculation of results using two different methods will
provide evidence about the robustness of results, while
informing broader discourse on methods for carrying out
economic evaluations alongside programs delivered at scale.
Each method has its strengths and limitations. The Monte
Carlo Simulation with patient level data approach will allow
for the incorporation of uncertainty around program costs
and is a more widely used technique than the net-benefit
regression approach. The net-benefit regression framework
will allow for cost-effectiveness to be calculated controlling
for other factors, which are unbalanced across arms in this
study. Comparing the two analytical approaches will stimu-
late discussion about when analysts should choose one over
the other when planning their analyses, particularly in the
context of evaluation of programs at scale.
Strengths and limitations
The main strength of this study is that it provides two
different analytic perspectives on cost-effectiveness,
allowing assessment of the robustness of results. It’s time
frame is comparable to other community-based studies,
although the full effect may not be captured as knowledge
takes time to fully proliferate, supply systems mature
through time, and changes in prescribing patterns can be
a gradual process. A heterogeneous mix of patients will be
included, enhancing the ability to generalize findings to
other areas in India. Recall bias is minimized by asking
only about episodes occurring in the last 2 weeks, in
keeping with precedent from a previous study [57].Overall, the quality of the data is high, with interviewers
returning to households to fill gaps in missing data.
The main limitation of this study is that the study design
of uncontrolled before and after studies is vulnerable to
bias, such as secular trends, the Hawthorne effect [48], or
regression to the mean [58]. However, the case for clinical
effectiveness can be made based on evidence from
randomized studies that have found reductions in the
prevalence of diarrhea when providers were enabled to
give zinc to children with diarrhea [10]. A CHERG review
concluded that zinc causes a 23% reduction in diarrhea-
specific mortality based on reductions in hospitalization
rates, reasoning that this estimate was realistic as it
was more conservative than reductions in all-cause or
diarrhea-specific mortality found in other studies [14].
This evidence is consistent with the 2004 WHO/UNICEF
endorsement of zinc for treating child diarrhea, which
concluded that zinc reduces the severity and duration of
acute diarrhea, and the number of episodes in the 2–3
months after treatment [8]. Since equipoise existed for the
DAZT delivery strategy, but not for the effectiveness of
zinc, the before and after study design was deemed to be
the appropriate form of evaluation [59]. The intervention
has since been rolled out statewide in Gujarat, and the
final survey is underway in Uttar Pradesh.
Secular trends such as improvements in living conditions,
access to safe water, and improved sanitation may have
contributed to the decline in diarrhea prevalence in the
DAZT study area [60]. However, secular trends may be
less relevant for costs as economic growth is unlikely to
drive prices for diarrhea treatment down. In addition, this
study design is sensitive to sudden changes in the condi-
tions of the study area [61]. The Hawthorne effect is a
potential confounder, which would overstate the magni-
tude of the effect [48]. Regression towards the mean may
be problematic [58], which means that if a study had high
diarrhea prevalence at beginning, future measurements
will be likely to be less extreme. The DAZT study found a
14% prevalence of diarrhea in 2011, while levels were 13%
in 2005/6 in Gujarat [36] and were 9% nationwide [7].
Regression to the mean predicts that the prevalence would
be lower in future surveys as downward changes would be
more frequent than upward changes.
Limitations exist in that household data is based on self-
report, reporting bias could have occurred, and long-term
outcomes and programmatic outcomes such as quality are
not measured. Some researchers argue that only children
who receive the recommended 10–14 day course should be
included in analysis. However, in the DAZT program, most
children only received partial courses of zinc in addition to
antibiotics and anti-diarrheal medications. Seasonal effects
are possible given that each survey was given at a differ-
ent point in the monsoon cycle across the years of the
study. Limitations of principal components analysis are
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assuming the first principal component to be an adequate
indicator of socioeconomic status, being a relative
measure, and producing quintiles with variable arrays of
asset ownership [53,62,63]. Finally, outcomes will not be
evaluated according to severity, which could lead to out-
comes such as children with fewer symptoms or shorter
episodes having more favorable cost-effectiveness.Targeting interventions according to subgroup
Cost-effectiveness according to subgroup can be assessed
in the net-benefit regression framework as the coefficients
on interaction terms between specific variables and the
treatment variable. However, the case exists that zinc for
diarrhea should not be targeted as it does not pose the
threat of microbial resistance that is relevant to antibiotics
and antimalarial medicines [64]. If widespread use of zinc
reduces the use of antibiotics, microbial resistance to them
may be slowed. In addition, zinc incurs only modest drug
costs per child, and the costs of rationing treatment may
outweigh the benefits of universal coverage [65]. In
addition, universal coverage may be justified on equity
grounds — while diarrhea affects people regardless of
socioeconomic status, mortality preferentially affects the
poor. Making treatments available according to patient
subgroups is justified according to treatment effect,
although is not justified according to demographic charac-
teristics such as race [66]. However, information on key
factors affecting effectiveness, such as or level of zinc status,
were not collected. In addition, the data structure produces
counterintuitive results as evaluating number of episodes
treated at different service providers implies episodes
averted when treatment seeking is reduced. For these
reasons, cost-effectiveness according to subgroup will not
be emphasized in this analysis.Generalizability
Results may be transferable to countries with similar health
systems and epidemiological profiles. Because of differences
in costs and similarities in efficacy of zinc across settings,
the case has been made that cost-effectiveness is likely to
vary more than effectiveness [22]. However, considerable
heterogeneity in effectiveness has been found across
settings, even within Asia [13], and results may be limited
in their generalizability in this dimension as well. Other
factors that may affect generalizability include ages of
children, duration of illness, health systems infrastructure,
receptiveness of health workers to changing treatment
practices, and use of other medicines to treat diarrhea.
Methodological assumptions may need adjustment as well,
including the discount rate and study perspective.
Descriptive statistics about the study setting will be
presented to facilitate discussion about generalizability.Abbreviations
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